180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.
Company profile
Ticker
ATNF
Exchange
Website
CEO
Jim N. Woody
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KBL MERGER CORP. IV
SEC CIK
Corporate docs
Subsidiaries
180 Life Corp. • Katexco Callco ULC • CannBioRex Callco ULC • 180 Therapeutics LP • Katexco Purchaseco ULC • CannBioRex Purchaseco ULC • Katexco Pharmaceuticals Corp. • CannBioRex Pharmaceuticals Corp. • CannBioRex Pharma Limited ...
ATNF stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Entry into a Material Definitive Agreement
9 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
8-K
Changes in Registrant's Certifying Accountant
19 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 675.98 k | 675.98 k | 675.98 k | 675.98 k | 675.98 k | 675.98 k |
Cash burn (monthly) | 433.27 k | 165.55 k | 697.49 k | 1.65 mm | 344.47 k | 673.81 k |
Cash used (since last report) | 684.82 k | 261.65 k | 1.10 mm | 2.61 mm | 544.46 k | 1.07 mm |
Cash remaining | -8.84 k | 414.32 k | -426.45 k | -1.94 mm | 131.52 k | -389.02 k |
Runway (months of cash) | -0.0 | 2.5 | -0.6 | -1.2 | 0.4 | -0.6 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 18 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.85 mm |
Total shares | 4.30 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
KBL Iv Sponsor | 2.22 mm | $5.47 mm |
Bauer Ronald | 1.41 mm | $7.02 mm |
Bridgman Craig | 673.51 k | $3.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Marc Feldmann | Common Stock | Grant | Acquire A | No | No | 0 | 135,377 | 0.00 | 250,874 |
15 Dec 23 | James N. Woody | Common Stock | Buy | Acquire P | No | No | 0.188 | 25,000 | 4.70 k | 66,888 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
17 May 24
12 Health Care Stocks Moving In Thursday's Intraday Session
16 May 24
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24